Company: RCUS
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001193125-25-028669
Chunk: 7

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 7
---
 programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and 
 prospects.                                                                                                                                                                                                                                              |

| • |     | Even if we receive marketing approval, we may not be successful in commercializing our investigational products. |

| • |     | Even if we receive marketing approval for one or more of our investigational products, our commercial success is                                                                                  
 dependent on obtaining coverage and reimbursement approval for a product from a government or other third-party payor, which coverage may be delayed or may not be sufficient to cover our costs. |

| • |     | Obtaining and maintaining regulatory approval of investigational products in one jurisdiction does not guarantee                                                                                                                               
 that we will be able to obtain or maintain regulatory approval in any other jurisdiction. Even if our investigational products are approved by the FDA, they may never be approved or commercialized outside the United States (“U.S.”), which 
 would limit our ability to realize their full market potential.                                                                                                                                                                                |

| • |     | Any investigational products for which we intend to seek approval as biologic products may face competition 
 sooner than anticipated.                                                                                    |

| • |     | We are currently party to several in-license agreements under which we                                                                                                                                                                                  
 acquired rights to use, develop, manufacture and/or commercialize certain of our investigational products. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these investigational products or 
 both, which would adversely affect our business and prospects.                                                                                                                                                                                          |

| • |     | If we are unable to obtain and maintain sufficient intellectual property protection for our investigational                                                                                                                                           
 products, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be 
 adversely affected.                                                                                                                                                                                                                                   |

| • |     | We may become involved in lawsuits alleging that we have infringed the intellectual property rights of third                                                                                                                
 parties or to protect or enforce our patents or other intellectual property, which litigation could be expensive, time consuming and adversely affect our ability to develop or commercialize our investigational products. |

| • |     | Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby 
 impairing our ability to protect our investigational products.                                                    |

S-4

| • |     | We may rely on trade secret and proprietary know-how which can be